I responded that management of osteoporosis with Zometa was then position-of-the-ability medicine still years beforehand of clinical trials, and that unreliable case studies such as this were often the source of ideas to be tested with clinical trials. The Amgen Senior Analyst said he would not consent any of my conclusions, nor allegedly would any competent certified, without a lookalike-blind excuse clinical burden. This same analyst told me after my speech that he had been invited to supervisor the Health Economics and Outcomes Research units at two other pharmaceutical companies, although based on his intolerant commentary, I honestly doubted it. Again, I responded to the Senior Analyst by asking if his own elderly mother or aunt or un. cle had previously suffered a bone break and was in hazard of having a radically condensed quality of life with any further break, would he rely on the weak FDA-approved oral bisphosphonates or try to get Zometa therapy for his own relatives? COURAGE THE COWARDLY DOG
He answered he would stick with the FDA-approved drugs, even if it meant his elderly parent would be injured with another hip crack from which he or she might not get well and would quickly get worse in bed and go to meet your maker. Next, a 6'3" board skilled radiologist, who for some unexplained reason gave up an annual salary of $350,000+ as a radiologist in private practice to become an industry scythe working for Amgen, carped that bisphosphonates, such as Zometa, do not actually inhibit the discharge of calcium from bones but instead strengthen the network organize of the bone. COURAGE THE COWARDLY DOG complete dvd box set series on DVDs Furthermore, my seminar included no go-to-leader comparisons of Zometa with Fosamax or Actonel or any other oral bisphosphonate, so he would not agree to the closin. I responded by means of asking the radiologist how several patients he had treated for osteoporosis whereas in concealed exercise. He responded "not a bit.
"I at the same time asked the radiologist if he knew the municipal-of-the-sculpture treatments for osteoporosis as of 2005, and he responded that the oral bisphosphonates were the pomp-of-the-knack. I then cutting out that no go on board expert oncologist would think about the oral bisphonates for treating cancer victims with undermined bone structures from chemotherapy. Oncologists need the medical comparable of a "howitzer" not a move quickly revolver to strengthen their cancer patients' bones, and oncologists' in drug for this behavior was Zometa. Osteoporosis has many of the same characteristics of destabilized bone shape and gloomy bone marble density as occurs with cancer patients who have undergone convinced types of chemotherapy. Despite his objections, I stood by my conclusions that Zometa was the best avail.
able medicine for osteoporosis, and I would mention it as a verve-discount therapy for elderly patients (male or female) susceptible to immobilizing fractures. I expected Amgen's Health Economics pole to be vigilant in recitation non-FDA permitted use of drugs, but I did not anticipate finding an entire responsibility filled with narrow-minded, rigid, demagogues incapable of thinking outside the box. To them, it was whichever the Amgen mode (attitude) or rejection mode at all. The Amgen HEOR junior analysts had acidic expressions on their faces during my talk, and when I asked them if they would let their own parents or grandparents expire from the incapacitating consequences of a hip fissure or get them Zometa therapy if needed, they took their cue from the 6'3" oncologist and said uniformly they would "let granny depart this life. " Do we certainly want callous people like this complex in tough the realm's drug pipeline?
After my squeal, I met additional baton in the Amgen HEOR org.